Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis
Increasing evidence links Alzheimer’s disease (AD) to various sleep disorders, including obstructive sleep apnea (OSA). The core AD cerebrospinal fluid (CSF) biomarkers, including amyloid-β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau), can reflect key elements of AD pathophysiology b...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.902408/full |
| _version_ | 1811240715714297856 |
|---|---|
| author | Wenqi Cui Zhenghao Duan Zijian Li Juan Feng |
| author_facet | Wenqi Cui Zhenghao Duan Zijian Li Juan Feng |
| author_sort | Wenqi Cui |
| collection | DOAJ |
| description | Increasing evidence links Alzheimer’s disease (AD) to various sleep disorders, including obstructive sleep apnea (OSA). The core AD cerebrospinal fluid (CSF) biomarkers, including amyloid-β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau), can reflect key elements of AD pathophysiology before the emergence of symptoms. Besides, the amyloid-β (Aβ) and tau burden can also be tested by positron emission tomography (PET) scans. Electronic databases (PubMed, Embase, Web of Science, and The Cochrane Library) were searched until August 2022 to assess the AD-related biomarkers measured by PET scans and CSF in OSA patients. The overall analysis showed significant differences in Aβ42 levels (SMD = −0.93, 95% CI:−1.57 to −0.29, P < 0.001) and total tau (t-tau) levels (SMD = 0.24, 95% CI: 0.01–0.48, P = 0.308) of CSF, and Aβ burden (SMD = 0.37, 95% CI = 0.13–0.61, P = 0.69) tested by PET scans between the OSA and controls. Furthermore, CSF Aβ42 levels showed significant differences in patients with moderate/severe OSA compared with healthy control, and levels of CSF Aβ42 showed differences in OSA patients with normal cognition as well. Besides, age and BMI have influences on heterogeneity. Our meta-analysis indicated abnormal AD-related biomarkers (CSF and PET scans) in patients with OSA, supporting the current hypothesis that OSA, especially moderate/severe OSA, may start the AD neuropathological process.Systematic review registration[https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42021289559]. |
| first_indexed | 2024-04-12T13:25:09Z |
| format | Article |
| id | doaj.art-71ef17922cb0468f84b0ade82c7955eb |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-04-12T13:25:09Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-71ef17922cb0468f84b0ade82c7955eb2022-12-22T03:31:21ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-10-011410.3389/fnagi.2022.902408902408Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysisWenqi CuiZhenghao DuanZijian LiJuan FengIncreasing evidence links Alzheimer’s disease (AD) to various sleep disorders, including obstructive sleep apnea (OSA). The core AD cerebrospinal fluid (CSF) biomarkers, including amyloid-β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau), can reflect key elements of AD pathophysiology before the emergence of symptoms. Besides, the amyloid-β (Aβ) and tau burden can also be tested by positron emission tomography (PET) scans. Electronic databases (PubMed, Embase, Web of Science, and The Cochrane Library) were searched until August 2022 to assess the AD-related biomarkers measured by PET scans and CSF in OSA patients. The overall analysis showed significant differences in Aβ42 levels (SMD = −0.93, 95% CI:−1.57 to −0.29, P < 0.001) and total tau (t-tau) levels (SMD = 0.24, 95% CI: 0.01–0.48, P = 0.308) of CSF, and Aβ burden (SMD = 0.37, 95% CI = 0.13–0.61, P = 0.69) tested by PET scans between the OSA and controls. Furthermore, CSF Aβ42 levels showed significant differences in patients with moderate/severe OSA compared with healthy control, and levels of CSF Aβ42 showed differences in OSA patients with normal cognition as well. Besides, age and BMI have influences on heterogeneity. Our meta-analysis indicated abnormal AD-related biomarkers (CSF and PET scans) in patients with OSA, supporting the current hypothesis that OSA, especially moderate/severe OSA, may start the AD neuropathological process.Systematic review registration[https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42021289559].https://www.frontiersin.org/articles/10.3389/fnagi.2022.902408/fullobstructive sleep apneaAlzheimer’s diseaseamyloid-β 42 (Aβ42)total tauphosphorylated tau (p-tau)PET scans |
| spellingShingle | Wenqi Cui Zhenghao Duan Zijian Li Juan Feng Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis Frontiers in Aging Neuroscience obstructive sleep apnea Alzheimer’s disease amyloid-β 42 (Aβ42) total tau phosphorylated tau (p-tau) PET scans |
| title | Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis |
| title_full | Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis |
| title_fullStr | Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis |
| title_full_unstemmed | Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis |
| title_short | Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis |
| title_sort | assessment of alzheimer s disease related biomarkers in patients with obstructive sleep apnea a systematic review and meta analysis |
| topic | obstructive sleep apnea Alzheimer’s disease amyloid-β 42 (Aβ42) total tau phosphorylated tau (p-tau) PET scans |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2022.902408/full |
| work_keys_str_mv | AT wenqicui assessmentofalzheimersdiseaserelatedbiomarkersinpatientswithobstructivesleepapneaasystematicreviewandmetaanalysis AT zhenghaoduan assessmentofalzheimersdiseaserelatedbiomarkersinpatientswithobstructivesleepapneaasystematicreviewandmetaanalysis AT zijianli assessmentofalzheimersdiseaserelatedbiomarkersinpatientswithobstructivesleepapneaasystematicreviewandmetaanalysis AT juanfeng assessmentofalzheimersdiseaserelatedbiomarkersinpatientswithobstructivesleepapneaasystematicreviewandmetaanalysis |